BA
NKTR icon

Bridgewater Associates’s Nektar Therapeutics NKTR Stock Holding History

Bridgewater Associates’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-738
Closed -$221K – 748
2021
Q1 		$221K Buy
+738
New +$230K ﹤0.01% 440

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridgewater Associates's NKTR Position: Q2 2021 in Review

Bridgewater Associates sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 738 shares — an estimated $221K sold.

Bridgewater Associates first reported a position in NKTR in Q1 2021 and held it in 1 quarter. The position peaked at $221K in Q1 2021. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

  • Bridgewater Associates reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bridgewater Associates sold 738 Nektar Therapeutics shares in Q2 2021, an estimated $221K.
  • Bridgewater Associates first reported a position in Nektar Therapeutics in Q1 2021 and held it in 1 quarter.
  • Bridgewater Associates's Nektar Therapeutics position peaked at $221K in Q1 2021.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on Bridgewater Associates's 13F filing for Q2 2021, filed 13 Aug 2021.